$heff's $tation of $tocks & $olid DD

[tripil7z]

$SYRS 13.90 in AH

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS) announced today that research from its scientific founders validates CDK12 and CDK13, members of the transcriptional cyclin-dependent kinase family that play a critical role in regulating gene expression, as promising new drug targets for a range of aggressive and difficult-to-treat cancers. These findings were possible as a result of the discovery of a highly selective CDK12 and CDK13 inhibitor by Syros’ scientific founders and underscore the potential of Syros’ pioneering approach for understanding and drugging transcriptional targets to advance a new wave of medicines that control the expression of disease-driving genes.


http://www.businesswire.com/news/home/20160829005099/en/Syros’-Scientific-Founders-Publish-Selective-CDK12-CDK13#.V8SWLlPsoz4.twitter